Related references
Note: Only part of the references are listed.Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy
Timothy P. Hughes et al.
BLOOD (2008)
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
Susan Branford et al.
BLOOD (2008)
Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories
M. C. Mueller et al.
LEUKEMIA (2008)
Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring - Summary and recommendations
Tong Zhang et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2007)
Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays:: towards new standards for gene expression measurements
J. Saldanha et al.
LEUKEMIA (2007)
An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR
Martin C. Mueller et al.
HAEMATOLOGICA (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia
S. Branford et al.
LEUKEMIA (2006)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Michele Baccarani et al.
BLOOD (2006)
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors:: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Timothy Hughes et al.
BLOOD (2006)
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
J Cortes et al.
CLINICAL CANCER RESEARCH (2005)
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
E Weisberg et al.
CANCER CELL (2005)
Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -: A Europe Against Cancer Program
J Gabert et al.
LEUKEMIA (2003)
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
TP Hughes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
